Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG

R. C. Reed, J. U. Gutterman, G. M. Mavligit, Evan M Hersh

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

BCG immunotherapy added to DTIC chemotherapy (BD) prolonged remission and survival compared to DTIC alone or with other drugs. The results of CI with DTIC, MeCCNU and BCG (DMB) are reported. MeCCNU was added since as a single agent, it induces an overall response rate of 17% in DM. Seventy three patients (pts) received DTIC 250 mg/m2 IV daily on days 1-5, MeCCNU 100 mg/m2 PO on day 1 and Tice BCG, 6 x 108 viable units by scarification on day 7, 12 and 17. Courses were repeated every 21 to 28 days. Among 64 pts with an adequate trial of DMB the overall response, complete remission (CR) partial remission (PR), stable (for >2 mth) and progression rates were 26, 14, 12, 40 and 34%, respectively compared to the BD regimen for which these rates were 27, 6, 21, 32 and 41%. The mean durations of remission (CR plus PR), stable disease, and survival for DMB were 6, 5 and 7 mth and for BD were 6, 4, and 7 mth. An additional 6 pts who had only brain metastases received Xray therapy followed by DMB. All are disease free at a median of 12+ mth. This was superior to the survival of an appropriate control group. The efficacy of BCG in DM is confirmed. The addition of MeCCNU has increased the CR rate and the percent of pts with stable DM. Continued low response rates particularly with visceral DM indicates the need for improved chemotherapy and delivery of immunotherapy to visceral sites.

Original languageEnglish (US)
Title of host publicationProceedings of the American Association for Cancer Research
Volume16
Edition66
StatePublished - 1975
Externally publishedYes

Fingerprint

Semustine
Mycobacterium bovis
Melanoma
Dacarbazine
Immunotherapy
Survival
X-Ray Therapy
Drug Therapy
imidazole
Neoplasm Metastasis
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reed, R. C., Gutterman, J. U., Mavligit, G. M., & Hersh, E. M. (1975). Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG. In Proceedings of the American Association for Cancer Research (66 ed., Vol. 16)

Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG. / Reed, R. C.; Gutterman, J. U.; Mavligit, G. M.; Hersh, Evan M.

Proceedings of the American Association for Cancer Research. Vol. 16 66. ed. 1975.

Research output: Chapter in Book/Report/Conference proceedingChapter

Reed, RC, Gutterman, JU, Mavligit, GM & Hersh, EM 1975, Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG. in Proceedings of the American Association for Cancer Research. 66 edn, vol. 16.
Reed RC, Gutterman JU, Mavligit GM, Hersh EM. Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG. In Proceedings of the American Association for Cancer Research. 66 ed. Vol. 16. 1975
Reed, R. C. ; Gutterman, J. U. ; Mavligit, G. M. ; Hersh, Evan M. / Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG. Proceedings of the American Association for Cancer Research. Vol. 16 66. ed. 1975.
@inbook{4ba001f100124387966bfec1f1222e16,
title = "Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG",
abstract = "BCG immunotherapy added to DTIC chemotherapy (BD) prolonged remission and survival compared to DTIC alone or with other drugs. The results of CI with DTIC, MeCCNU and BCG (DMB) are reported. MeCCNU was added since as a single agent, it induces an overall response rate of 17{\%} in DM. Seventy three patients (pts) received DTIC 250 mg/m2 IV daily on days 1-5, MeCCNU 100 mg/m2 PO on day 1 and Tice BCG, 6 x 108 viable units by scarification on day 7, 12 and 17. Courses were repeated every 21 to 28 days. Among 64 pts with an adequate trial of DMB the overall response, complete remission (CR) partial remission (PR), stable (for >2 mth) and progression rates were 26, 14, 12, 40 and 34{\%}, respectively compared to the BD regimen for which these rates were 27, 6, 21, 32 and 41{\%}. The mean durations of remission (CR plus PR), stable disease, and survival for DMB were 6, 5 and 7 mth and for BD were 6, 4, and 7 mth. An additional 6 pts who had only brain metastases received Xray therapy followed by DMB. All are disease free at a median of 12+ mth. This was superior to the survival of an appropriate control group. The efficacy of BCG in DM is confirmed. The addition of MeCCNU has increased the CR rate and the percent of pts with stable DM. Continued low response rates particularly with visceral DM indicates the need for improved chemotherapy and delivery of immunotherapy to visceral sites.",
author = "Reed, {R. C.} and Gutterman, {J. U.} and Mavligit, {G. M.} and Hersh, {Evan M}",
year = "1975",
language = "English (US)",
volume = "16",
booktitle = "Proceedings of the American Association for Cancer Research",
edition = "66",

}

TY - CHAP

T1 - Chemoimmunotherapy (CI) of disseminated malignant melanoma (DM) with imidazole carboxamide (DTIC), a nitrosourea (MeCCNU) and BCG

AU - Reed, R. C.

AU - Gutterman, J. U.

AU - Mavligit, G. M.

AU - Hersh, Evan M

PY - 1975

Y1 - 1975

N2 - BCG immunotherapy added to DTIC chemotherapy (BD) prolonged remission and survival compared to DTIC alone or with other drugs. The results of CI with DTIC, MeCCNU and BCG (DMB) are reported. MeCCNU was added since as a single agent, it induces an overall response rate of 17% in DM. Seventy three patients (pts) received DTIC 250 mg/m2 IV daily on days 1-5, MeCCNU 100 mg/m2 PO on day 1 and Tice BCG, 6 x 108 viable units by scarification on day 7, 12 and 17. Courses were repeated every 21 to 28 days. Among 64 pts with an adequate trial of DMB the overall response, complete remission (CR) partial remission (PR), stable (for >2 mth) and progression rates were 26, 14, 12, 40 and 34%, respectively compared to the BD regimen for which these rates were 27, 6, 21, 32 and 41%. The mean durations of remission (CR plus PR), stable disease, and survival for DMB were 6, 5 and 7 mth and for BD were 6, 4, and 7 mth. An additional 6 pts who had only brain metastases received Xray therapy followed by DMB. All are disease free at a median of 12+ mth. This was superior to the survival of an appropriate control group. The efficacy of BCG in DM is confirmed. The addition of MeCCNU has increased the CR rate and the percent of pts with stable DM. Continued low response rates particularly with visceral DM indicates the need for improved chemotherapy and delivery of immunotherapy to visceral sites.

AB - BCG immunotherapy added to DTIC chemotherapy (BD) prolonged remission and survival compared to DTIC alone or with other drugs. The results of CI with DTIC, MeCCNU and BCG (DMB) are reported. MeCCNU was added since as a single agent, it induces an overall response rate of 17% in DM. Seventy three patients (pts) received DTIC 250 mg/m2 IV daily on days 1-5, MeCCNU 100 mg/m2 PO on day 1 and Tice BCG, 6 x 108 viable units by scarification on day 7, 12 and 17. Courses were repeated every 21 to 28 days. Among 64 pts with an adequate trial of DMB the overall response, complete remission (CR) partial remission (PR), stable (for >2 mth) and progression rates were 26, 14, 12, 40 and 34%, respectively compared to the BD regimen for which these rates were 27, 6, 21, 32 and 41%. The mean durations of remission (CR plus PR), stable disease, and survival for DMB were 6, 5 and 7 mth and for BD were 6, 4, and 7 mth. An additional 6 pts who had only brain metastases received Xray therapy followed by DMB. All are disease free at a median of 12+ mth. This was superior to the survival of an appropriate control group. The efficacy of BCG in DM is confirmed. The addition of MeCCNU has increased the CR rate and the percent of pts with stable DM. Continued low response rates particularly with visceral DM indicates the need for improved chemotherapy and delivery of immunotherapy to visceral sites.

UR - http://www.scopus.com/inward/record.url?scp=0016738147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016738147&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:0016738147

VL - 16

BT - Proceedings of the American Association for Cancer Research

ER -